ALT
Altimmune, Inc.
6.53
USD
This page is just a preview of the data found in TrendSpider’s full version
Altimmune, Inc. stock is up 141.85% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 63.16% of the previous 18 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 07 Dec 16:28 | 17 Jan, 2025 | 20.00 | 280 | ||
| 07 Dec 16:49 | 15 Dec, 2023 | 8.00 | 2594 | ||
| 07 Dec 16:50 | 19 Jan, 2024 | 5.00 | 7612 | ||
| 07 Dec 16:50 | 19 Jan, 2024 | 5.00 | 7612 | ||
| 07 Dec 16:55 | 17 Jan, 2025 | 20.00 | 280 | ||
| 07 Dec 16:56 | 17 Jan, 2025 | 20.00 | 280 | ||
| 07 Dec 17:09 | 15 Dec, 2023 | 3.00 | 4524 | ||
| 07 Dec 17:13 | 19 Jan, 2024 | 10.00 | 2452 | ||
| 07 Dec 17:29 | 15 Dec, 2023 | 5.00 | 3063 | ||
| 07 Dec 18:57 | 19 Jan, 2024 | 8.00 | 2054 |
Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
